Erectile Dysfunction Overview and Treatment Considerations in Special Populations

被引：0

作者：

Snoga, Jenna L. ^{[1
]}

Williams, Briana ^{[1
]}

Courtney, Lindsay A. ^{[2
]}

机构：

[1] Univ Incarnate, Dept Pharm Practice, Word Feik Sch Pharm, San Antonio, TX 78209 USA

[2] Texas Tech Univ, Dept Pharm Practice, Hlth Sci Ctr, Jerry H Hodge Sch Pharm, Amarillo, TX USA

来源：

US PHARMACIST | 2022年 / 47卷 / 06期

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Erectile dysfunction (ED) is a common urologic condition that causes distress in men. Risk factors and predictors for ED include age, cardiovascular disease (CVD), hypertension, diabetes, smoking, and certain medications. CVD and ED share several risk factors, and ED may be a predictor of future cardiovascular events. Lifestyle modifications and phosphodiesterase type 5 inhibitors (PDE5Is) are considered first-line therapies for ED. PDE5Is can be less effective in patients with diabetes and should be used cautiously in certain patients with CVD. This review explores treatment options for ED with a focus on those with a history of diabetes or CVD.

引用

页码：18 / 22

页数：5